1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

13. Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, GoldeDW, Scheinberg DA, Zelenetz AD, Weiss MA. Sequential therapy with fludarabine, high-dosecyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemiaproduces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol27(4): 491-7, 2009. PMID: 1907528014. Santos EB, Yeh R, Lee J, NIkhamin Y, Punzalan B, Punzalan B, La Perle K, Larson SM, Sadelain M,Brentjens RJ. Sensitive in vivo imaging of T cells utilizing a membrane bound Gaussia princeps luciferase.Nat Med 15 (3):338-44, 2009. PMID: 1921902315. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V,Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Riviere I. Manufacturing validation of biologicallyfunctional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 32: 169-80,2009. PMID: 1923801616. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia withgenetically targeted autologous T cells: A case report of an unforeseen adverse event in a phase I clinical trial.Mol Ther 18:666-8, 2010. PMID: 2035777917. Na IK, Markley JC, Tsai JJ, Yim NL, Beattie BJ, Klose AD, Holland AM, Ghosh A, Rao UK, Stephan MT,Serganova I, Santos EB, Brentjens RJ, Blasberg RG, Sadelain M, van den Brink MR. Concurrentvisualization of T lymphocytes and T cell precursors in vivo. Blood. 2010 Sep 16;116(11):e18-25. Epub 2010May 28. PMID: 2051154118. Lee J, Hayman E, Pegram H, Santos E, Heller G, Sadelain M, Brentjens RJ. In vivo inhibition of humanCD19 targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cellmalignancy. Can Res (in press).19. Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR, Brentjens RJ. Successfuleradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cellsgenetically targeted to the MUC16 antigen. Clin Can Res 16:3594-606, 2010 PMID: 2062803020. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M. CARson Track in the Clinic. Heslop HE. Mol Ther. 2011 Mar;19(3):432-8. PMID: 2135870521. Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. In vivo Inhibition of HumanCD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B CellMalignancy. Cancer Res. 2011 Apr 15;71(8):2871-81. Epub 2011 Apr 12. PMID: 2148703822. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, HoseyJ, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safetyand persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed orchemotherapy refractory B-cell leukemias. Blood. 2011 Nov 3;118(18):4817-28. Epub 2011 Aug 17. PMID:2184948623. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ.Tumor-targeted T cellsmodified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012 Feb 21.[Epub ahead of print] PMID:2235400116